Inder Verma will receive the 22nd annual Robert J. and Claire Pasarow Award in Cancer Research for fundamental basic research throughout his career. The award is designed to recognize distinguished accomplishments in basic and/or clinical research while increasing public awareness of vital areas of investigation.
Verma will share the award with Brian Druker, M.D., director of the Knight Cancer Institute, for his role in developing Gleevec, a powerful drug used to treat chronic myeloid leukemia.
Verma, holder of Irwin and Joan Jacobs Chair in Exemplary Science and a professor in Salk's Laboratory of Genetics, has made outstanding advances in research ranging from cancer biology to development of gene transfer technologies. He is one of the world's leading authorities in gene therapy, having developed a vector, based on a stripped-down version of HIV, that successfully delivers genes for therapeutic purposes. His innovations revolutionized gene therapy, stem cell and cancer research, among other areas of molecular biology.
An American Cancer Society Professor, Verma is a member of the National Academy of Sciences, Institute of Medicine, American Inside Salk April 2010 www.salk.edu 27 Academy of Arts & Sciences, American Philosophical Society and Third World Academy of Sciences. He is the recipient of numerous awards, including: the 2009 Outstanding Achievement Award from the American Society of Gene Therapy; the 2008 Vilcek Prize; the 2010 Spector Prize; and the 2007 Cozzarelli Prize. Verma will receive the Pasarow award, which includes a $50,000 prize that he will share with Druker, at a dinner in Los Angeles later this year.